The Medicines Co. Newsletter
-
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
18 Jun 2025 11:00 GMT
… clinical-stage diabetes and obesity medicines company, today announced new preclinical findings … clinical-stage diabetes and obesity medicines company focused on the development of …
-
Biomea Fusion Announces Pricing of Public Offering of Securities
18 Jun 2025 03:15 GMT
… clinical-stage diabetes and obesity medicines company focused on the development of …
-
Biomea Fusion Announces Proposed Public Offering of Securities
17 Jun 2025 20:33 GMT
… clinical-stage diabetes and obesity medicines company focused on the development of …
-
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 Jun 2025 12:16 GMT
… clinical-stage, non-viral genetic medicines company, today reported the grant of …
-
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 Jan 2025 14:00 GMT
… become a diabetes and obesity medicines company. Based on the most recent …
-
Biotechs Chroma, Nvelop merge to form genetic medicines company
11 Dec 2024 12:29 GMT
-
SpliceBio Raises $135M Series B to Advance SB-007 for Stargardt Disease
13 Jun 2025 11:05 GMT
SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address …
-
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
13 Jun 2025 10:45 GMT
… clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical … clinical-stage diabetes and obesity medicines company focused on the development of …
-
Layoffs hit another Massachusetts genetic medicines company
14 Oct 2024 17:50 GMT
-
Alnylam's founding CEO is back with another RNAi-based medicines company
08 Oct 2024 17:00 GMT